Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients
Background The programme death ligand1 and its receptor (PD-1/PD-L1) interaction is a target for block age by immunotherapy that uses the body’s own immune system. Some studies show that PD-L1 expressing tumours are also more aggressive with poor prognosis. This study evalu ated the immunohistochemi...
Saved in:
| Format: | Article |
|---|---|
| Published: |
2022
|
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Programme death ligand 1 expressions as a surrogate for determining immunotherapy in cervical carcinoma patients
- PD-L1 expression patterns in stage IB1 cervical squamous cell carcinoma: a retrospective study on implications for tumor budding and immune microenvironment
- Deciphering diverse cell‐death patterns to predict the prognosis and potential therapy target of hepatocellular carcinoma patients
- MRI differentiation of usual type endocervical adenocarcinoma and cervical squamous cell carcinoma
- Death and Survival of Patients with Hansen
- Expression of Concern: TMEM41A overexpression correlates with poor prognosis and immune alterations in patients with endometrial carcinoma
- Calcium-related genes predict prognosis, immune characteristics, and response to immunotherapy in LUAD patients